ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

Aurobindo Pharma will manufacture & supply long-acting injectable HIV treatment cabotegravir across 133 countries, including ...

Aurobindo Pharma to manufacture and supply long-acting injectable HIV treatment in 133 countries, offering alternative to ...

ViiV & MPP extend voluntary licensing long-acting injectable HIV treatment, Indian pharma to benefit: Our Bureau, Bengaluru Tuesday, July 15, 2025, 12:45 Hrs [IST] ViiV Healthcare ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

Plaintiffs allege that CRISP and its subsidiary willfully infringed on patented technology by launching a copycat product after terminating a long-standing licensing agreement.

The Delhi High Court has declined a plea moved by US-based Kroll Information Assurance, seeking to patent 'System to locate ...